Statement: None of the adverse events recorded for the primary trial occurred more than once.
Primary_evidence: Adverse Events 1:   Total: 21/82 (25.61%)   Neutrophils count decreased 1/82 (1.22%)   Cardiac ischemia/infarction 1/82 (1.22%)   Left ventricular systolic dysfunction 1/82 (1.22%)   Hypertension 1/82 (1.22%)   Supraventricular and nodal arrhythmia 1/82 (1.22%)   Anorexia 1/82 (1.22%)   Gastrointestinal perforation 1/82 (1.22%)   Vomiting 1/82 (1.22%)   Dehydration 1/82 (1.22%)   Diarrhoea 1/82 (1.22%)